Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Kieran Durkin is active.

Publication


Featured researches published by Kieran Durkin.


Bioorganic & Medicinal Chemistry Letters | 1999

Discovery of FR166124, a novel water-soluble pyrazolo-[1,5-a]pyridine adenosine A1 receptor antagonist

Satoru Kuroda; Atsushi Akahane; Hiromichi Itani; Shintaro Nishimura; Kieran Durkin; Takayoshi Kinoshita; Yoshiyuki Tenda; Kazuo Sakane

Novel 3-(2-cycloalkyl and cycloalkenyl-3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazo lo [1,5-a]-pyridines were synthesized and evaluated for their adenosine A1 receptor binding activities. In this series, FR166124 (3) was found to be the most potent and selective adenosine A1 receptor antagonist, and the double bond of the cyclohexenyl acetic acid group was essential for selectivity of A1 receptor binding. Furthermore, the solubility in water of the sodium salt of FR 166124 was high.


Bioorganic & Medicinal Chemistry Letters | 2011

3-Amino-pyrazolo[3,4-d]pyrimidines as p38α kinase inhibitors: Design and development to a highly selective lead

Michael Soth; Sarah C. Abbot; Allassan Abubakari; Nidhi Arora; Humberto Bartolome Arzeno; Roland Joseph Billedeau; Nolan James Dewdney; Kieran Durkin; Sandra Frauchiger; Manjiri Ghate; David Michael Goldstein; Ronald J. Hill; Andreas Kuglstatter; Fujun Li; Brad Loe; Kristen Lynn Mccaleb; Joel McIntosh; Eva Papp; Jaehyeon Park; Martin Stahl; Man-Ling Sung; Rebecca T. Suttman; David C. Swinney; Paul Weller; Brian Wong; Hasim Zecic; Tobias Gabriel

Learnings from previous Roche p38-selective inhibitors were applied to a new fragment hit, which was optimized to a potent, exquisitely selective preclinical lead with a good pharmacokinetic profile.


Bioorganic & Medicinal Chemistry | 2000

Novel adenosine A1 receptor antagonists. Synthesis and structure-activity relationships of a novel series of 3-(2-cyclohexenyl-3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5 -a]pyridines.

Satoru Kuroda; Atsushi Akahane; Hiromichi Itani; Shintaro Nishimura; Kieran Durkin; Yoshiyuki Tenda; Kazuo Sakane

A novel series of 3-(2-cyclohexenyl-3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazol o[1,5-a]pyridines was synthesized and evaluated for in vitro adenosine A1 and A2A receptor binding activities. Most of the cyclohexenyl derivatives (7a-e, 8a-s) were found to be potent adenosine A1 receptor antagonists. In a series of analogues of FR166124 (3a), alcohol 7c, nitrile 7e and amide derivatives (7d, 8c, 8r) were found to be more potent A1 antagonists with higher A2A/A1 selectivity than FR166124. Amongst them, 8r showed considerable water solubility (33.3 mg/mL), but lower than that of the sodium salt of FR166124 (> 200 mg/mL). Additionally, FR166124 had strong diuretic activity by both p.o. and iv administration in rats (minimum effective dose=0.1 and 0.032 mg/kg, respectively).


Tetrahedron | 1999

SYNTHESIS OF THE WATER-SOLUBLE ADENOSINE A1 RECEPTOR ANTAGONIST FR166124 THROUGH A NOVEL SEQUENTIAL HORNER-EMMONS/ISOMERIZATION REACTION

Satoru Kuroda; Atsushi Akahane; Hiromichi Itani; Shintaro Nishimura; Kieran Durkin; Takayoshi Kinoshita; Isao Nakanishi; Kazuo Sakane

Abstract An efficient synthesis of FR166124 ( 1 ) was achieved through a novel sequential Horner-Emmons -isomerization reaction of cyclohexanone ( 2 ) with tert -butyl diethylphosphonoacetate ( 3 ) as the key process. Extensive studies of the key reaction indicated that temperature, base and conformation of the Horner-Emmons products were important factors in the isomerization reaction, leading to a proposed mechanism for this unusual Horner-Emmons reaction.


Archive | 2004

Processes for preparing 4’azido nucleoside derivatives

Terrence Joseph Connolly; Kieran Durkin; Keshab Sarma; Jiang Zhu


Archive | 2006

P38 map kinase inhibitors and methods for using the same

Nidhi Arora; Humberto Bartolome Arzeno; Roland Joseph Billedeau; Nolan James Dewdney; Kieran Durkin; Tobias Gabriel; Kristen Lynn Mccaleb; Michael Soth; Dennis Mitsugu Yasuda


Archive | 1994

Pyrazolopyridine adenosine antagonists

Atsushi Akahane; Shintaro Nishimura; Hiromichi Itani; Kieran Durkin


Archive | 2006

Inhibitoren der p38-map-kinase und verfahren zu deren anwendung

Nidhi Arora; Humberto Bartolome Arzeno; Roland Joseph Billedeau; Nolan James Dewdney; Kieran Durkin; Tobias Gabriel; Kristen Lynn Mccaleb; Michael Soth; Dennis Mitsugu Yasuda


Archive | 2004

Verfahren zur herstellung von 4'-azidonukleosidderivaten

Joseph Terrence Redwood City Connolly; Kieran Durkin; Keshab Sarma; Jiang Zhu


Archive | 2004

A method for producing nucleoside-4azido

Terrence Joseph Connolly; Kieran Durkin; Keshab Sarma; Jiang Zhu

Collaboration


Dive into the Kieran Durkin's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge